Drug Trial Radar · NCT06402513
A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe
Last checked: Nov 19, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jun 24, 2024
Primary completion
Oct 8, 2024
Study completion Oct 8, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the pharmacokinetics, immunogenicity, safety, and tolerability, of subcutaneous formulation of ravagalimab in a pre-filled syringe in healthy adult participants.
Conditions
- Healthy Volunteers
Interventions
RavagalimabDrug
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax)Time frame: Approximately up to 71 days
- Time to Maximum Observed Plasma Concentration (Tmax)Time frame: Approximately up to 71 days
- Apparent Terminal Phase Elimination Rate Constant (β)Time frame: Approximately up to 71 days
- The Terminal Phase Elimination Half-Life (t1/2)Time frame: Approximately up to 71 days
- The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)Time frame: Approximately up to 71 days
- The Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC∞)Time frame: Approximately up to 71 days
- Number of Anti-drug antibody (ADA) TitersTime frame: Approximately up to 71 days
- Number of Participants with Adverse EventsTime frame: Approximately up to 85 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 265325
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.